Recombinant Rat CTSK Protein (115-329 aa), His-tagged

• Cat.No.: CTSK-439R
• Product Overview: Recombinant Rat CTSK Protein (115-329 aa) is produced by E. coli expression system. This protein is fused with a 6xHis tag at the N-terminal. Protein Description: Full Length of Mature Protein.

Specification

• Description: Closely involved in osteoclastic bone resorption and may participate partially in the disorder of bone rodeling. Displays potent endoprotease activity against fibrinogen at acid pH. May play an important role in Extracellular domain matrix degradation.
• Source: E. coli
• Species: Rat
• Tag: His
• Form: Tris-based buffer, 50% glycerol
• Molecular Mass: 27.5 kDa
• Protein length: 115-329 aa
• AA Sequence: VPDSIDYRKKGYVTPVKNQGQCGSC WAFSSAGALEGQLKKKTGKLLALSP QNLVDCVSENYGCGGGYMTTAFQYV QQNGGIDSEDAYPYVGQDESCMYNA TAKAAKCRGYREIPVGNEKALKRAV ARVGPVSVSIDASLTSFQFYSRGVY YDENCDRDNVNHAVLVVGYGTQKGN KYWIIKNSWGESWGNKGYVLLARNK NNACGITNLASFPKM
• Purity: > 90% as determined by SDS-PAGE.
• Notes: Repeated freezing and thawing is not recommended. Store working aliquots at 4 centigrade for up to one week.
• Storage: The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself. Generally, the shelf life of liquid form is 6 months at -20 centigrade/-80 centigrade. The shelf life of lyophilized form is 12 months at -20 centigrade/-80 centigrade.
• Concentration: A hardcopy of COA with concentration instruction is sent along with the products.

Gene Information

• Gene Name: Ctsk cathepsin K [ Rattus norvegicus ]
• Official Symbol: CTSK
• Synonyms: CTSK; cathepsin K
• Gene ID: 29175
• mRNA Refseq: NM_031560
• Protein Refseq: NP_113748
• UniProt ID: O35186

Reviews

09/13/2019

This guidance can help researchers design and execute their experiments more effectively, ensuring reliable and accurate results.

01/27/2019

They have a deep understanding of the CTSK protein and can provide valuable insights into its characteristics, properties, and optimal experimental conditions.

12/14/2016

the manufacturer offers outstanding technical support, serving as a valuable resource to resolve any issues that may arise during my research.

Q&As

Can CTSK be a target for the development of novel therapeutics for periodontal diseases?

Yes, CTSK inhibitors are being investigated for their potential in preventing bone loss associated with periodontal diseases.

How does CTSK contribute to the progression of atherosclerosis, and can it be a therapeutic target for cardiovascular diseases?

CTSK has been linked to vascular calcification in atherosclerosis, and inhibiting its activity may have potential as a therapeutic strategy for cardiovascular diseases.

How might CTSK inhibitors impact the treatment landscape for bone metastasis in cancer patients?

CTSK inhibitors could potentially be used to limit bone destruction in cancer patients with bone metastasis, improving their quality of life.

Are there any other medical conditions where CTSK inhibitors could be beneficial?

CTSK inhibitors are being explored for potential therapeutic applications in conditions like rheumatoid arthritis and certain cancers due to their involvement in tissue remodeling.

Are there diagnostic applications for CTSK in identifying bone-related disorders?

While CTSK is not currently used as a diagnostic marker, its levels and activity could potentially be explored for diagnostic purposes in the future.